M&A Deal Summary

Genzyme Acquires Novazyme Pharmaceuticals

On September 27, 2001, Genzyme acquired life science company Novazyme Pharmaceuticals from Aisling Capital for 137M USD

Acquisition Highlights
  • This is Genzyme’s 3rd transaction in the Life Science sector.
  • This is Genzyme’s 8th largest (disclosed) transaction.
  • This is Genzyme’s 5th transaction in the United States.
  • This is Genzyme’s 1st transaction in Oklahoma.

M&A Deal Summary
Date 2001-09-27
Target Novazyme Pharmaceuticals
Sector Life Science
Buyer(s) Genzyme
Sellers(s) Aisling Capital
Deal Type Add-on Acquisition
Deal Value 137M USD

Target

Novazyme Pharmaceuticals

Oklahoma City, Oklahoma, United States
Novazyme is a development stage biotechnology company focused on drugs to treat lysosomal storage diseases

Search 201,429 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Genzyme

Cambridge, Massachusetts, United States
Category Company
Founded 1981
Sector Life Science
DESCRIPTION
Genzyme laboratory in Framingham, Massachusetts.
Genzyme laboratory in Framingham, Massachusetts.

Genzyme is a global biotech company. Genzyme's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant and immune disease. Genzyme was formed in 1981 and is based in Cambridge, Massachusetts.

DEAL STATS #
Overall 5 of 12
Sector (Life Science) 3 of 9
Type (Add-on Acquisition) 4 of 10
State (Oklahoma) 1 of 1
Country (United States) 5 of 9
Year (2001) 1 of 1
Size (of disclosed) 8 of 9
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2000-12-25 GelTex Pharmaceuticals

Waltham, Massachusetts, United States

GelTex Pharmaceuticals, Inc. engaged in developing and marketing non-absorbed polymer drugs

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2003-09-10 SangStat Medical

Fremont, California, United States

SangStat Medical Corp. is a biotechnology company focused on immunology and working to discover, develop and market high value therapeutic products in the autoimmune, hematology/oncology and immunosuppression areas.

Buy $600M

Seller(S) 1

SELLER

Aisling Capital

New York, New York, United States

Investor Investor Investor Investor Investor

Category Private Equity Firm
Founded 2000
PE ASSETS 1.8B USD
Size Large
Type Sector Focused
DESCRIPTION

Aisling Capital is a private investment firm focused on opportunities in the healthcare and medical technology sectors. The Firm specifically looks to invest in companies developing and commercializing innovative healthcare products, services, and technologies. Aisling Capital looks to commit $20 to $50 million per investment and prefers to be the lead investor. Aisling will consider investing in both public and private companies. Aisling Capital raised its first fund in 2000. The Firm is based in New York City.

DEAL STATS #
Overall 1 of 41
Sector (Life Science) 1 of 32
Type (Add-on Acquisition) 1 of 24
State (Oklahoma) 1 of 1
Country (United States) 1 of 41
Year (2001) 1 of 1
Size (of disclosed) 11 of 12
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2001-08-28 Myogen

Westminster, Colorado, United States

Myogen is a Development stage biotechnology company focused on cardiovascular drugs. Myogen has two product candidates in late-stage clinical development: ambrisentan for the treatment of patients with pulmonary arterial hypertension (PAH) and darusentan for the treatment of patients with resistant hypertension.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2002-08-01 Oculex Pharmaceuticals

Sunnyvale, California, United States

Oculex Pharmaceuticals, Inc. is an Ophthalmic drug delivery company.

Buy -
Mergr

Product

Company

Legal